Home › Funds › Krensavage Asset Management, LLC › RARE
Krensavage Asset Management, LLC position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
Krensavage Asset Management, LLC reported holding 390,879 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q2 2026 13F filing — a position valued at US$13.1M, representing 4.96% of its reported portfolio and ranking #9 among its reported holdings. Krensavage Asset Management, LLC has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Krensavage Asset Management, LLC's RARE position evolved
Krensavage Asset Management, LLC first disclosed a stake in RARE in Q4 2025 at 149,634 shares (US$3.4M). The position peaked in Q2 2026 at 390,879 shares, worth US$13.1M. Across 3 filings, Krensavage Asset Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 390,879 shares valued at US$13.1M. Notable position changes include a 161% increase in Q1 2026 (shares rose 59% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 149.63K | $3.44M | New |
| Q1 2026 | 390.88K | $8.19M | Add |
| Q2 2026 | 390.88K | $13.05M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 27 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), SANDS CAPITAL MANAGEMENT, LLC (US$105.5M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- SANDS CAPITAL MANAGEMENT, LLC 3.16M sh · $105.46M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
More on Krensavage Asset Management, LLC
FAQ
How long has Krensavage Asset Management, LLC held RARE?
Krensavage Asset Management, LLC has disclosed RARE holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Krensavage Asset Management, LLC's current position in RARE?
As of Q2 2026, Krensavage Asset Management, LLC holds 390.88K shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $13.05M, representing 4.96% of its reported portfolio and ranking #9.
Has Krensavage Asset Management, LLC been buying or selling RARE?
In the latest 13F filing (Q2 2026), Krensavage Asset Management, LLC held unchanged its position in RARE. The position peaked in Q2 2026 at 390.88K shares.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, SANDS CAPITAL MANAGEMENT, LLC, FRONTIER CAPITAL MANAGEMENT CO LLC, among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.